CHRS - CIK 0001512762
The table below shows Coherus BioSciences, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $88.88M | $125.99M | $102.89M | $63.55M | $417.19M | $541.16M |
| Short-term investments | $83.25M | $14.86M | $14.86M | $128.13M | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | $3.17M | $70.09M | $62.60M | $38.79M | $37.64M | $44.23M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $206.71M |
| $341.58M |
| $475.63M |
| $381.23M |
| $602.32M |
| $767.48M |
| Property, plant & equipment | $1.34M | $2.84M | $5.12M | $8.75M | $7.81M | - |
| Goodwill | - | $943.00K | $943.00K | $900.00K | $943.00K | $943.00K |
| Total assets | $258.34M | $448.53M | $629.60M | $480.85M | $679.33M | $841.65M |
| Accounts payable | $9.91M | $28.46M | $35.22M | $11.53M | $16.16M | $15.20M |
| Total current liabilities | $140.39M | $282.98M | $331.77M | $138.69M | $165.33M | $145.65M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $197.33M | $580.52M | $823.03M | $618.26M | $581.61M | $560.67M |
| Retained earnings | -$1.38B | -$1.55B | -$1.58B | -$1.34B | -$1.05B | -$762.75M |
| Total equity | $61.01M | -$131.99M | -$193.43M | -$137.42M | $97.73M | $280.97M |